185 related articles for article (PubMed ID: 34027993)
1. Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Kim SC; Schneeweiss S
Clin Pharmacol Ther; 2022 Jan; 111(1):179-186. PubMed ID: 34027993
[TBL] [Abstract][Full Text] [Related]
2. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy.
Kirchgesner J; Desai RJ; Schneeweiss MC; Beaugerie L; Kim SC; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2022 Feb; 31(2):167-175. PubMed ID: 34498314
[TBL] [Abstract][Full Text] [Related]
3. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Kirchgesner J; Desai RJ; Schneeweiss MC; Beaugerie L; Schneeweiss S; Kim SC
Gut; 2022 Sep; 71(9):1781-1789. PubMed ID: 35387877
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.
Meyer A; Rudant J; Drouin J; Weill A; Carbonnel F; Coste J
Ann Intern Med; 2019 Jan; 170(2):99-107. PubMed ID: 30534946
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Tsoulis DJ; MacDonald JK
Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
10. Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab.
Sousa P; Patita M; Arroja B; Lago P; Rosa I; de Sousa HT; Ministro P; Mocanu I; Vieira A; Castela J; Moleiro J; Roseira J; Cancela E; Portela F; Correia L; Santiago M; Dias S; Alves C; Afonso J; Dias CC; Magro F
Dig Liver Dis; 2024 May; 56(5):737-743. PubMed ID: 37980274
[TBL] [Abstract][Full Text] [Related]
11. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
12. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
Bouguen G; Sninsky C; Tang KL; Colombel JF; DʼHaens G; Kornbluth A; Mantzaris GJ; Rachmilewitz D; Reinisch W; Rutgeerts P; Molenda M; Jannekevan der Woude C; Sandborn WJ
Inflamm Bowel Dis; 2015 Mar; 21(3):606-14. PubMed ID: 25581826
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of infliximab and adalimumab for Crohn's disease.
Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger C; Chen L; Xie F; Curtis JR; Lewis JD
Clin Gastroenterol Hepatol; 2014 May; 12(5):811-817.e3. PubMed ID: 23811254
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate for maintenance of remission in Crohn's disease.
Patel V; Wang Y; MacDonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006884. PubMed ID: 25157445
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
19. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
20. Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study.
Lund K; Larsen MD; Knudsen T; Kjeldsen J; Nielsen RG; Mertz Nørgård B
J Crohns Colitis; 2021 Apr; 15(4):575-582. PubMed ID: 32926166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
